HEMO Hemogenyx Pharmaceuticals Plc

9.093USD690.50 GBp · LSE+3.06%Mkt Cap: 62.71M USDP/E: —

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company'…

Key Statistics

Company
Market Cap62.71M USD
Enterprise Value56.33M USD
Revenue (TTM)—
Gross Profit-1.22M USD
Net Income (TTM)-12.85M USD
Revenue/Share—
Last Price9.093 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BQVXM815
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-3.69
EV/Revenue—
P/S—
P/B10.86
EPS (TTM)-1.74 USD
EPS (Forward)—
52W Range
4.68839% of range16.07
52W High16.07 USD
52W Low4.688 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-816.50%
ROA-233.73%
ROIC-298.34%
ROCE-172.22%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.54M USD
CapEx (TTM)5.16K USD
FCF Margin—
FCF Yield-3.10%
Net Debt-3.60M USD
Net Debt/EBITDA0.24
Net Debt/FCF—
Balance Sheet
Debt/Equity1.68
Current Ratio4.04
Quick Ratio4.04
Book Value/Sh0.84 USD
Cash/Share0.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:400
Split DateDec 13, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.90M
Float5.27M
Insiders29.02%
Institutions0.40%
Technical
SMA 507.792 (+16.7%)
SMA 2009.825 (-7.4%)
Beta1.48
S&P 52W Chg12.08%
Avg Vol (30d)17.77K
Avg Vol (10d)13.38K
Technical Indicators
RSI (14)55.8
MACD12.2906
MACD Signal6.3727
MACD Hist.+5.9179
BB Upper9.751 USD
BB Middle8.481 USD
BB Lower7.212 USD
BB Width29.93%
ATR (14)1.176 USD
Vol Ratio (20d)0.34x

About Hemogenyx Pharmaceuticals (LON: HEMO)

›

Hemogenyx Pharmaceuticals (LON: HEMO) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.

The shares were at 690.50 GBp on 19 November 2026, down 19.3% over 52 weeks. Its 52-week range is 356.00 GBp to 1220.00 GBp: the price is 43.4% below the high and 94.0% above the low.

Its market capitalisation is 47.62M GBP.

Hemogenyx Pharmaceuticals reports an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 2.73M GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.